Acute recumbency associated with Anaplasma phagocytophilum infection in a horse

An 11-year-old Hanoverian-cross gelding was evaluated because of acute onset of ataxia, recumbency, and fever. At the stable, this and other horses had recently been infested with ticks. Results of analysis of a sample of CSF were within reference limits, but hematologic abnormalities included lymphopenia, thrombocytopenia, mild anemia, and intracytoplasmic inclusion bodies in neutrophils that were consistent with Anaplasma phagocytophilum (previously Ehrlichia equi). Results of serum biochemical analyses were characteristic of infection and included high, unconjugated bilirubin concentration. Other common causes of recumbency in horses, such as equine protozoal myeloencephalitis, infection with eastern or western equine encephalitis viruses and equine herpesvirus-1, West Nile viral encephalitis, trauma, and metabolic disease, were ruled out. The horse responded quickly to i.v. administration of oxytetracycline and recovered fully within 6 days.     

Short-duration exercise and confinement alters bone mineral content and shape in weanling horses

The hypothesis that short-duration exercise may ameliorate the decrease in bone mass observed with confinement was investigated with 18 quarter horses (nine colts and nine fillies) weaned at 4 mo of age and placed into box stalls. After a 5-wk adjustment period, individuals were grouped by age and weight, and then divided randomly into three treatment groups: 1) group housed; 2) confined with no exercise; and 3) confined with exercise. The confined and exercised groups were housed in 3.7 m x 3.7 m box stalls for the 56-d duration of the trial. The exercised group was sprinted 82 m/d, 5 d/wk, in a fenced grass alleyway. The weanlings were led down an alleyway, turned loose in a small pen, and then released and allowed to run back down the alley. The group horses were housed together in a 992-m2 drylot with free access to exercise. On d 0, 28, and 56, dorsopalmar and lateromedial radiographs of the left third metacarpal bone were taken to estimate changes in bone mineral content and cortical widths. Mean values of medial, lateral, and total radiographic bone aluminum equivalence increased over time (P < 0.05), whereas dorsal and palmar radiographic bone aluminum equivalence did not change significantly. Dorsal, medial, and total radiographic bone aluminum equivalence tended (P = 0.09) to differ by a treatment x day interaction, with values increasing over time only in the exercised group. Normalized medial and total radiographic bone aluminum equivalence tended (P < 0.1) to differ (P < 0.01) with treatment, with exercised horses having greater bone aluminum equivalence than confined horses. Dorsopalmar cortical width in exercised horses was greater than on d 56 (treatment x day; P = 0.07). The dorsopalmar medullary cavity decreased in exercised vs. group-housed horses (P = 0.027), whereas dorsal and medial cortical width tended to increase only in the exercised horses (treatment x day; P < 0.01). This study indicated that a short-duration exercise protocol might be effective in improving bone mass and therefore skeletal strength in horses.     

Salmonella enteritidis clearance and immune responses in chickens following Salmonella vaccination and challenge

Our previous work showed that the cell-mediated immunity (CMI) was enhanced by live Salmonella vaccine (LV). The objective of this study was to evaluate the impact of live and killed Salmonella vaccines on Salmonella enteritidis (SE) clearance and to determine if the clearance was mediated by cell-mediated and/or humoral immunity. Chickens were first immunized at 2 weeks of age followed by a booster dose at 4 weeks, challenged with live SE 2 weeks later (6-week-old) and tested for CMI, antibody response and SE clearance 1-week post SE-challenge (7-week-old). Spleen cell proliferation induced by SE-flagella and Concanavalin A (Con A) were significantly higher and SE shedding was significantly lower in the LV group. The splenic CD3 population was significantly lower and B cells were higher in the control group compared to all the SE-challenged groups (with and without vaccination). Serum antibody to SE-flagella and envelope were significantly higher in the KV group compared to all the other groups. These results suggest that LV protects against SE infection, probably by enhancing the CMI.     

Comparison of three methods of feeding sows in gestation and the subsequent effects on lactation performance

A total of 684 sows from breeding groups over 6 wk was used to compare three methods of feeding during gestation on gestation and lactation performance. Control gilts and sows were fed according to body condition based on a scale of 1 to 5 (1 = thin, 5 = fat). Sows were visually assessed for body condition at breeding and were assigned a daily feed allowance to achieve a BCS of 3 at farrowing. Treatment 2 used feeding levels based on backfat thickness (measured between d 0 and 5 after breeding) and weight at weaning for sows or service for gilts. Feed allowance was calculated to achieve a target backfat of 19 mm at farrowing, and remained constant from d 0 to 101 of gestation. Feed allowances were based on modeled calculations of energy and nutrient requirements to achieve target sow maternal weight and backfat gains. Treatment 3 was identical to Treatment 2, except that feeding pattern was altered for thin sows and gilts (<15 mm at service) in an attempt to reach 19 mm by d 36 of gestation. Sows were weighed at the previous weaning, and gilts were weighed at service, with both weighed again between d 112 and 114 of gestation. Backfat was measured between d 0 and 5, and again between d 108 and 113 of gestation. At farrowing, sows on Treatments 2 and 3 had 19 and 19.1 mm of backfat, respectively, whereas control sows tended to have greater (P < 0.07) backfat (20 mm). On average, sows targeted to gain 6 to 9 mm of backfat failed to reach target gains regardless of feeding method. Feeding sows in gestation based on backfat (Treatments 2 and 3) resulted in a numerically higher proportion of sows in the target backfat range of 17 to 21 mm (40.2, 53.3, and 52.6% for control and Treatments 2 and 3, respectively) at farrowing and a numerically lower percentage of fat sows (>21 mm), but no difference in the percentage of thin sows (<17 mm) compared with feeding based on body condition. In conjunction with this observation, sows fed based on BCS were fed higher (P < 0.05) feeding levels in gestation than were sows fed based on backfat depth. Gestation feeding method had no effect on performance during lactation. Feed intake in lactation was lower (P < 0.05) for high backfat sows (>21 mm) at farrowing compared with sows with <21 mm. The high proportion of sows in the optimal backfat category demonstrates that feeding based on backfat and BW has potential for facilitating more precise feeding during gestation.     

Effect of anionic salt and highly fermentable carbohydrate supplementations on urine pH and on experimentally induced hypocalcaemia in cows

The objective of this experiment was to determine the effect of dietary grain on calcium homeostasis. Six rumen-fistulated dairy cows with 3 or more previous lactations and no history of parturient paresis were randomly assigned to a sequence of diets in a crossover study with 4 periods of 10 days each. Dietary treatments were: A control ration consisting of wrap grass silage alone (1), the control ration supplemented with ammonium chloride and ammonium sulphate salt solution (2), control ration following a period with supplementation (3) and control ration supplemented with increasing amounts of barley from 4 to 10 kg/cow per day, expected to produce subclinical rumen acidosis (4). Daily intake of the diets was adjusted to 14 kg DM/cow per day. On day 11, the calcium-regulating mechanisms in cows were challenged until recumbency by a standardized intravenous EDTA infusion and cows were left to recover spontaneously. Anion supplementation and the feeding of highly fermentable carbohydrate lowered urine pH below 7.0 due to subclinical acidosis. During spontaneous recovery from EDTA induced hypocalcaemia, the cows more quickly regained a whole blood free calcium concentration of 1.00 mmol/L if they had most recently been supplemented with either anionic salts or with increasing amounts of barley, as compared to the basic ration. It is concluded that so-called slug-feeding or 'steaming up' with highly fermentable carbohydrates before parturition in milk fever susceptible cows enhanced calcium homeostasis similar to the effect seen in cows on anionic diets.     

Pulmonic stenosis in dogs: balloon dilation improves clinical outcome

Medical records of 81 dogs with severe pulmonic stenosis from 2 referral centers were examined retrospectively. Forty dogs underwent balloon valvuloplasty (BV), which was performed by 1 operator, whereas 41 did not. The mean age at latest follow-up was 41.5 months. A statistical comparison of the clinical outcome and survival was performed. Dogs revealing clinical signs at presentation showed a 16-fold increase in risk of death compared with asymptomatic dogs (P < .001). Statistical analyses demonstrated that an increase of 1 mm Hg in transstenotic pressure gradient (PG) at presentation was associated with a 3% increase in hazard rate (P < .001). Thirty-seven dogs survived BV with a median reduction in PG of 46%. The median preoperative PG was 120 mm Hg, and median PG 24 hours postoperatively was 55 mm Hg with a median of 55 mm Hg 6 months post-BV. Twenty (49%) of the non-BV (NBV) dogs remained asymptomatic at last follow-up. Fourteen (34%) of the NBV dogs died or were euthanized because of heart disease related to pulmonic stenosis. Twelve of these dogs died suddenly, whereas only 1 of the BV dogs died suddenly. After adjusting for PG, clinical signs at presentation, and age, BV or dilation was associated with a 53% reduction in hazard rate (P = .005). This study indicates that BV, when performed by an experienced operator, appears to be successful both in alleviating clinical signs and in prolonging survival in dogs with severe pulmonic stenosis.     

In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis

OBJECTIVE: To determine cyclooxygenase-2 (COX-2) selectivity, pharmacokinetic properties, and in vivo efficacy of ML-1,785,713 in dogs. ANIMALS: 21 healthy male and female mixed-breed dogs and 24 healthy male Beagles. PROCEDURE: Selectivity of ML-1,785,713 for inhibiting COX-2 was determined by comparing the potency for inhibiting cyclooxygenase-1 (COX-1) with that of COX-2 in canine blood. Pharmacokinetic properties were determined after i.v. (2 mg/kg) and oral (8 mg/kg) administration in female mixed-breed dogs. In vivo efficacy was evaluated in male mixed-breed dogs with urate crystal-induced synovitis. Prophylactic efficacy was evaluated by administering ML-1,785,713 two hours before induction of synovitis whereas therapeutic efficacy was determined by administering ML-1,785,713 one hour after induction of synovitis. RESULTS: Blood concentrations that resulted in 50% inhibition of COX-1 and COX-2 activity in vitro were 119.1 microM and 0.31 microM, respectively, and selectivity ratio for inhibiting COX-2 relative to COX-1 was 384. ML-1,785,713 had high oral bioavailability (101%), low systemic clearance (77 mL/min/kg), and an elimination half-life of 5.9 hours. ML-1,785,713 was efficacious when administered prophylactically and therapeutically to dogs with urate crystal-induced synovitis. CONCLUSIONS AND CLINICAL RELEVANCE: ML-1,785,713 is a novel, potent COX-2 inhibitor that is the most selective COX-2 inhibitor described for use in dogs to date. ML-1,785,713 has oral bioavailability and low systemic clearance that is comparable to other non-steroidal anti-inflammatory drugs. It is effective after prophylactic and therapeutic administration in attenuating lameness in dogs with urate crystal-induced synovitis. Drugs that specifically inhibit COX-2 and not COX-1 at therapeutic doses may have an improved tolerability profile, compared with nonselective non-steroidal anti-inflammatory drugs.